PRESS RELEASE published on 11/03/2025 at 14:30, 6 months 7 days ago NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd NanoViricides, Inc. to present groundbreaking antiviral drug NV-387 at Spartan Capital Investor Conference. CEO Diwan to update on drug pipeline & Platform Technologies for licensing NanoViricides NV-387 Clinical Trial Antiviral Drug Spartan Capital Investor Conference
BRIEF published on 10/29/2025 at 13:50, 6 months 12 days ago NV-387: A Promising Antiviral Agent for Measles NanoViricides NV-387 Clinical Trials Antiviral Research Measles Treatment
BRIEF published on 10/29/2025 at 13:50, 6 months 12 days ago NV-387 : un agent antiviral prometteur contre la rougeole NanoViricides NV-387 Essais Cliniques Recherche Antivirale Traitement De La Rougeole
PRESS RELEASE published on 10/29/2025 at 13:45, 6 months 12 days ago Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive NanoViricides, Inc. announced progress in antiviral research with their drug NV-387 showing potent activity against Measles virus. Clinical trials have shown safety and effectiveness, positioning for emergency use NanoViricides NV-387 Clinical Trials Antiviral Research Measles Virus
BRIEF published on 10/27/2025 at 13:50, 6 months 14 days ago NanoViricides Set to Present at PODD 2025 Conference NanoViricides NV-387 Biotechnology Clinical Trials Antiviral Drug
BRIEF published on 10/27/2025 at 13:50, 6 months 14 days ago NanoViricides sera présenté à la conférence PODD 2025 NanoViricides NV-387 Biotechnologie Essais Cliniques Médicament Antiviral
PRESS RELEASE published on 10/27/2025 at 13:45, 6 months 14 days ago NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 NanoViricides, Inc. to present at PODD 2025 Conference with focus on revolutionary broad-spectrum antiviral drugs in development for various viral infections Respiratory Viral Infections NV-387 Antiviral Drugs NanoViricides, Inc. PODD 2025 Conference
BRIEF published on 10/22/2025 at 14:50, 6 months 19 days ago Le NV-387 s'avère prometteur contre la rougeole et protège les poumons NV-387 Essais Cliniques Antiviral Rougeole Protection Pulmonaire
BRIEF published on 10/22/2025 at 14:50, 6 months 19 days ago NV-387 Shows Promise Against Measles, Protects Lungs NV-387 Clinical Trials Antiviral Lung Protection Measles
PRESS RELEASE published on 10/22/2025 at 14:45, 6 months 19 days ago In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides NanoViricides, Inc. announces promising results for drug NV-387 against Measles virus, showing dual benefits in cell culture and animal models. NV-387 also demonstrates safety and unique mechanism of action NanoViricides NV-387 Clinical Trial Antiviral Drug Measles Virus
Published on 05/09/2026 at 01:30, 1 day 23 hours ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 2 days ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/10/2026 at 16:05, 8 hours 54 minutes ago RingConn Gen 3 Smart Ring Opens for Pre-Order: Bringing Vascular Insights to Effortless Everyday Wear
Published on 05/10/2026 at 14:00, 10 hours 59 minutes ago MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Published on 05/10/2026 at 11:45, 13 hours 14 minutes ago Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Published on 05/09/2026 at 19:05, 1 day 5 hours ago LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 2 days 4 hours ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/07/2026 at 19:15, 3 days 5 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 3 days 5 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 3 days 5 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 3 days 5 hours ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 3 days 5 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL